Back to search

Peptide record

TPDB43139

B1-Gly Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB43139
B1-Gly
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
VKRFKKFFRKLKKGV-NH2
Physicochemical Analysis
C93H157N27O16
ANDCEQHIMPSTWY
K
1909.44
12.46
8
0
6
+8
3.76
-0.813
64.67
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
1
L
6
K
0
M
3
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 6 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
15
C93H157N27O16
1909.44
12.46
+8
3.76
-0.813
Amidation
L
Linear
Free
Antimicrobial and Anticancer
Synthetic analog of B1
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 15.8 µM
Anticancer
15.8 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 14.8 µM
Anticancer
14.8 µM

Target

Leukemia cancer
K-562
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015